ClinicalTrials.gg
RecruitingNCT07482579Updated Mar 25, 2026

Development of Stroke Prognosis Predictive Precision Medicine Based on a Digital Twin

An observational study in Stroke, sponsored by Seyoung Shin. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Seyoung Shin · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Stroke with a site in Korea, Republic of — 41 open to participants now, 49 under way, 2 of them phase 3. Stroke · Korea, Republic of.

Planned enrollment
50th of 61
70 · median 150
Started
2025
with 13 others
Observational
62 of 279
16 open now
Primary completion
2026-12
later than 27 of 48 live
Registered
269th of 279
by date

Among the 279 studies in Stroke with a site in Korea, Republic of, this one is the 50th largest by planned enrollment of the 61 observational ones that give a count, is one of 14 that started in 2025, is one of 62 observational ones, reaches primary completion later than 27 of the 48 other live ones, and was the 269th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

41 of the 279 studies in Stroke with a site in Korea, Republic of are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Stroke with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To collect large-scale, high-quality clinical data, daily activity and movement patterns, and genomic information from stroke patients spanning the subacute to chronic stages.

This study aims to establish the foundation for personalized precision medicine in stroke care and to develop a visual and digital transformation of patient medical information in the era of digital healthcare.

Read the detailed description

This study aims to establish a comprehensive, high-quality dataset that captures the longitudinal characteristics of stroke recovery from the subacute to chronic stages. By integrating clinical data, daily activity and movement patterns, and genomic information, the study reflects the multidimensional nature of stroke in a real-world setting.

The collected data will support data-driven approaches in stroke care by enabling a better understanding of individual variability in recovery trajectories and facilitating the development of predictive models for functional outcomes.

In addition, this study seeks to contribute to personalized precision medicine by enabling individualized interpretation of patient data. It also supports the digital transformation of healthcare by facilitating structured, visual, and data-driven representations of patient medical information for improved clinical and research applications.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Stroke patients receiving treatment at two hospitals in Korea

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 years or older with a confirmed diagnosis of stroke.
  • Within 1 month after stroke onset.
  • Patients scoring between 0 and 3 points on the Functional Ambulatory Category (FAC) test.
  • Patients or their legally authorized representatives who have fully understood the details of this study, voluntarily decided to participate, and provided written to comply with the study instructions.

Exclusion criteria

Exclusion Criteria:

  • Patients with impaired ability to provide consent ( score less than 10) who are not accompanied by a caregiver.
  • Any other cases deemed inappropriate for participation by the investigator. (This study is non-interventional; therefore, patients who are currently participating in or have participated in another clinical study or research within the past 30 days may still be included.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Stroke patients

    Patients diagnosed with stroke at two hospitals in Korea

    Other: Stroke

Interventions

  • OtherStroke

    No intervention

06

What researchers measure

Primary outcomes

  1. Modified Barthel Index (MBI)

    A scale to measure disability or dependence in activities of daily living (ADL) of stroke survivors (range 0-100)

    Time frame: minimum <1 months to maximum 6 months

  2. Mini Mental Status Examination (MMSE)

    Mini-Mental State Examination (MMSE) is a 30-question assessment of cognitive function that evaluates attention and orientation, memory, registration, recall, calculation, language and ability to draw a complex polygon (range 0-30)

    Time frame: minimum <1 months to maximum 6 months

  3. Functional Ambulatory Category (FAC)

    The Functional Ambulation Categories (FAC) is a 6-point functional walking test that evaluates ambulation ability, determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device. (range 0-5)

    Time frame: minimum <1 months to maximum 6 months

  4. Fugl-Meyer Assessment (FMA)

    The Fugl-Meyer Assessment (FMA) is a performance-based scale used to evaluate motor functioning, balance, sensation, and joint functioning in patients who have experienced a stroke. The motor domain (score range 0-100) assesses movement, coordination, and reflexes of the upper and lower extremities, with higher scores indicating better motor recovery.

    Time frame: minimum <1 months to maximum 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 13 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07482579
Lead sponsor
Seyoung Shin
Responsible party
Seyoung Shin (Principal Investigator, CHA University) — Sponsor-investigator
First posted
Mar 19, 2026
Start date
Nov 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 25, 2026

Study contacts

Seyoung Shin, MD
Contact
seyoung0706@chamc.co.kr
+82437505000
Seyoung Shin, MD
principal investigator · CHA University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion